Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.
复制标题

DOI:
10.1002/pbc.24315
复制
发表时间:
2012-12-15
影响因子:
3.2
通讯作者:
Biegel, Jaclyn A.
Biegel, Jaclyn A.
中科院分区:
医学3区
文献类型:
--
作者:
Kieran, Mark W.;Roberts, Charles W. M.;Chi, Susan N.;Ligon, Keith L.;Rich, Benjamin E.;MacConaill, Laura E.;Garraway, Levi A.;Biegel, Jaclyn A.

文献摘要

参考文献

被引文献

相似文献

横纹肌样瘤(也称为脑中的非典型畸胎瘤/横纹肌样瘤(AT/RT))是发生在肾脏、软组织和中枢神经系统中的高度恶性、预后不良的病变。这种疾病的靶向治疗将受益于检测相关可操作突变的先进技术。在这里,我们报告了25个肿瘤的评估,所有已知SMARCB 1/INI 1改变,在115个癌基因和肿瘤抑制基因中存在983个不同的突变,使用OncoMap,一种等位基因检测的质谱方法。除了SMARCB 1突变,我们的结果在NRAS中发现了一个单一的激活突变,并且在所有其他测试的基因中完全不存在致癌突变。在对成人癌症的发展和进展至关重要的典型途径中缺乏突变表明,不同的机制驱动这些高度恶性的儿科肿瘤。这可能会限制现有靶向治疗的治疗效用,并需要重新关注发育和表观遗传途径。
Rhabdoid tumors (also called atypical teratoid/rhabdoid tumor (AT/RT) in the brain), are highly malignant, poor prognosis lesions arising in the kidneys, soft tissues and central nervous system. Targeted therapy in this disease would benefit from advanced technologies detecting relevant actionable mutations. Here we report on the evaluation of twenty-five tumors, all with known SMARCB1/INI1 alterations, for the presence of 983 different mutations in 115 oncogenes and tumor-suppressor genes using OncoMap, a mass spectrometric method of allele detection. Other than mutations in SMARCB1, our results identified a single activating mutation in NRAS and complete absence of oncogenic mutations in all other genes tested. The absence of mutations in canonical pathways critical for development and progression of adult cancers suggests that distinct mechanisms drive these highly malignant pediatric tumors. This may limit the therapeutic utility of available targeted therapies and require a refocusing toward developmental and epigenetic pathways.
DOI: 10.1038/modpathol.2010.112
发表时间: 2010-09
期刊: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
影响因子: --
作者:
Rivera M;Ricarte-Filho J;Knauf J;Shaha A;Tuttle M;Fagin JA;Ghossein RA
通讯作者: Ghossein RA
DOI: 10.1002/path.2103
发表时间: 2007-02-01
影响因子: 7.3
作者:
Bourdeaut, F.;Freneaux, P.;Delattre, O.
通讯作者: Delattre, O.
DOI: 10.1182/blood-2010-04-279083
发表时间: 2010-09-16
期刊: BLOOD
影响因子: 20.3
作者:
Badalian-Very, Gayane;Vergilio, Jo-Anne;Rollins, Barrett J.
通讯作者: Rollins, Barrett J.
DOI: 10.1093/neuonc/nor140
发表时间: 2011-12-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Birks, Diane K.;Donson, Andrew M.;Foreman, Nicholas K.
通讯作者: Foreman, Nicholas K.
DOI: 10.4161/cbt.8.5.8019
发表时间: 2009-03
影响因子: 3.6
作者:
Roberts CW;Biegel JA
通讯作者: Biegel JA